Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit ...

Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a standard of care.

Supernus believes that with Zurzuvae joining its three other key growth products, Qelbree, ONAPGO, and GOCOVRI, the company is poised for significant future growth.

This increase was primarily due to cash generated from operations partially offset by the $25.0 million payment of ONAPGO-related milestone in the first quarter of 2025.

During the Phase 3 study, ONAPGO significantly reduced the amount of daily OFF time at 12 weeks from baseline (p=0.0114), with ONAPGO-treated patients (n=53) experiencing a 2.6-hour reduction ...

ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for total ...

ONAPGO (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025.

Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued growth of our core products, and strong growth in ...

ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for ...

Onapgo joins a Supernus Parkinson’s drug lineup that includes Apokyn, an injection pen product that administers apomorphine, and Gocovri, a capsule approved to treat dyskinesia and off time in ...

Earlier this month, the FDA approved Supernus Pharmaceuticals’ ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device ...